424 results on '"Jurcic, Joseph G"'
Search Results
2. NPM1 and FLT3-TKD mutations are enriched in patients with leukemia cutis
3. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
4. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
5. Targeted radionuclide therapy of hematologic malignancies
6. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
7. Targeted Alpha-Particle Therapy for Hematologic Malignancies
8. Rewriting the rules for care of MDS and AML patients in the time of COVID-19
9. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
10. AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results
11. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
12. A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
13. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
14. Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML
15. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
16. Response to COVID-19 Infection and Vaccination in the CLL Population: A Large Single-Center Experience
17. Monoclonal Antibody Therapy of Cancer
18. Targeted α-Particle Therapy : A Rational Approach to Drug Development in Hematological Diseases and Solid Tumors
19. A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia
20. Rapidly adapting the clinical research environment at an NCI-designated comprehensive cancer center to the COVID-19 pandemic.
21. Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
22. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death
23. Radiolabeled Monoclonal Antibodies
24. Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant—New Drugs on the Horizon for Acute Myeloid Leukemia
25. A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia
26. Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab
27. Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine
28. High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL)
29. Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia
30. Targeting RARAoverexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
31. What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?
32. Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study
33. Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
34. Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.
35. Diagnosis and treatment of acute promyelocytic leukemia
36. Severe mechanical hemolysis in a patient with thalassemia minor who had undergone inappropriate splenectomy
37. Immunotherapy for acute myeloid leukemia
38. Targeted Alpha-Particle Therapy for Hematologic Malignancies
39. Monitoring PML-RARα in acute promyelocytic leukemia
40. Childhood, Adolescent and Young Adult Acute Myeloid Leukemias
41. Radioimmunotherapy for hematopoietic cell transplantation
42. Radioimmunotherapy of Acute Myeloid Leukemia
43. Novel Therapeutics for Chemotherapy-Resistant Acute Myeloid Leukaemia
44. Antibody immunotherapy for leukemia
45. Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia
46. A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results
47. MDS-179: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study
48. MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS)
49. Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).
50. Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.